Two medicines, side by side
Carvedilol vs losartan
Carvedilol and losartan are both labeled for high blood pressure. Drugs@FDA records approvals of carvedilol since 1995 and of losartan since 1995. Pharmacies paid $0.0179 per carvedilol 6.25 mg tablet and $0.0327 per losartan potassium 50 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, carvedilol is an alpha-adrenergic blocker and losartan an angiotensin 2 receptor blocker.
Check it at the source: the carvedilol FDA label on DailyMed (effective July 31, 2026); the losartan FDA label on DailyMed (effective January 20, 2026).
Highlights of the carvedilol record
Carvedilol (Coreg) · label of July 31, 2026
Used for
From the label: indicationsINDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in […]
On the market
- Earliest approval on file
- September 14, 1995
- Generic labelers
- 41 labelers
- Pharmacy cost
- $0.0179 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 22
Highlights of the losartan record
Losartan (Cozaar) · label of January 20, 2026
FETAL TOXICITY When pregnancy is detected, discontinue COZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue COZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Used for
From the label: indicationsCOZAAR is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. […]
On the market
- Earliest approval on file
- April 14, 1995
- Generic labelers
- 43 labelers
- Pharmacy cost
- $0.0327 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 77
Source: FDA drug labels via openFDA (Carvedilol label of July 31, 2026, Losartan label of January 20, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do carvedilol and losartan differ on the record?
In FDA's classes, carvedilol is an alpha-adrenergic blocker and losartan an angiotensin 2 receptor blocker.
How each works, in its label's words: Carvedilol, “COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers …”; Losartan, “Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the …”
Half-life, in each label's words: Carvedilol, “Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 …”; Losartan, “The terminal half-life of losartan is about 2 hours and of the metabolite is about 6-9 hours.”
Only the losartan label carries a boxed warning.
Generics: carvedilol since 2007; losartan since 2010 (Drugs@FDA).
| Carvedilol | Losartan | |
|---|---|---|
| Labeled for | Heart failure, High blood pressure | High blood pressure, Chronic kidney disease, Stroke prevention |
| Pharmacologic class | alpha-Adrenergic Blocker, beta-Adrenergic Blocker | Angiotensin 2 Receptor Blocker |
| How it works (label) | COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. | Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component … |
| Half-life (label) | Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours. | The terminal half-life of losartan is about 2 hours and of the metabolite is about 6-9 hours. |
| Earliest approval on file (Drugs@FDA) | September 14, 1995 | April 14, 1995 |
| First generic approved | September 5, 2007 | April 6, 2010 |
| Generic labelers (NDC) | 41 labelers | 43 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0179 per tablet (Carvedilol 6.25 mg tablet) | $0.0327 per tablet (Losartan potassium 50 mg tablet) |
| 12-month price change | -4% | +2% |
| Boxed warning | No | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 22 | 77 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 137,029 | 200,566 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to carvedilol
- every medicine labeled for the same conditions